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1. Introduction 
In 1886, Fränkel first described pheochromocytoma at autopsy 1. The term 
pheochromocytoma was coined by Poll in 1905 to describe the dusky (pheo) color (chromo) 
of the cut surface of the tumour when exposed to dichromate 2. Not until 1926 did Mayo 
3 at the Mayo Clinic and Roux 4 in Switzerland successfully remove these adrenal 
tumours. Interestingly, neither of these tumours was diagnosed preoperatively. 
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumours arising 
from the chromaffin cells of the embryonic neural crest mainly of adrenal medulla or the 
extra-adrenal chromaffin tissue (paraganglia). Which synthesize, store, metabolize, and 
usually but not always secrete catecholamines.  
1.1 Incidence 
Population studies report an annual incidence of between 0.4 and 9.5 new cases per 100,000 
adult persons each year 5,6,7, which constitute a curable form of hypertension in 0.1 to 1% 
of hypertension patients 8. Of patients with pheochromocytoma discovered only at 
autopsy, 75% died suddenly from either myocardial infartion or a cerebrovascular 
catastrophe. Moreover, one third of the sudden deaths occurred during or immediately after 
unrelated minor operations 9,10. Referrals for pheochromocytoma have been reported to 
be increasing, likely as a result of improved detection. 
1.2 Clinical features 
The majority of pheochromocytomas are sporadic in origin (80-90%) but may be associated 
with other diseases. Classically, pheochromocytomas has been termed a “10% tumour 
because roughly 10% of these tumours are malignant, multifocal, and bilateral, arise in 
extra-adrenal sites, and occur in children. However, recent evidence suggests the percentage 
of familial tumours is considerably higher 11.  
1.3 Classic presentation 
The classic triad of pheochromocytoma presentation is episodic headache, sweating, and 
palpitations. Manifestations of catecholamine excess form a wide spectrum of symptoms in 
www.intechopen.com
 Pheochromocytoma – A New View of the Old Problem 
 
4 
these patients, the foremost being hypertension. Persistent hypertension is frequently 
considered part of the presentation. Also is typically found with a diverse set of symptoms, 
which may include anxiety, chest and abdominal pain, visual blurring, papilledema, nausea 
and vomiting, orthostatic hypotension, transitory electrocardiographic changes, and 
psychiatric disorders. As to be expected, these symptoms are not always present and 
certainly do not always constitute a diagnosis. Nonfunctioning pheochromocytomas are 
distinctly uncommon; nearly all patients with these tumours, at least in retrospect, 
demonstrate some characteristic symptom or sign, especially accentuated at the time of 
operative tumour manipulation. Diagnosis of pheochromocytoma includes detection of 
catecholamines in urine and plasma and radiological tests such as computed axial 
tomography, nuclear magnetic resonance imaging and metaiodobenzylguanidine 
scintigraphy. Laparoscopic techniques have become standard for treatment of tumours of 
the adrenal glands 12.  
2. Pathology features 
2.1 Macroscopy findings 
Nearly 90% of pheochromocytomas are usually confined to the adrenal gland, and may 
appear encapsulated. In sporadic pheochromocytomas, even though lobulated, the tumour 
is actually a single neoplasm. In contrast, familial tumours are often bilateral and usually 
multicentric 13. Pheochromocytomas are of variable size, ranging from 3 cm to 5 cm in 
diameter but can be more than 10 cm 14. The weight may range from < 5g to over 3,500g, 
the average in patients with hypertension being 100g 15. The cut surface is usually soft, 
yellowish white to reddish brown. The larger tumours often have areas of necrosis, 
hemorrhage, central degenerative change, cystic change and calcification. The normal gland 
can be seen in most cases but is sometimes attenuated (Fig. 1).  
 
 
Fig. 1. Adrenal Pheochromocytoma. The round tumour extends torwards the adrenal cortex 
but is macroscopically well defined. Focal degenerative change and central hemorrhage is 
present. Attached adrenal remnant is also present.  
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The other 10 to 15% of cases are found in the neck, mediastinum and heart, or along the 
course of the sympathetic chain. The most frequent extra-adrenal site is the aortic 
bifurcation, the so-called organ of Zuckerkandl 16.  
2.2 Histopathology 
Microscopically, the tumour cells are characteristically arranged in well-defined nest 
(“Zellballen”) or trabecular pattern bound by a delicate fibrovascular stroma, or a mixture of 
the two (Fig. 2A). Diffuse or solid architecture can also be seen. A true capsule does not 
usually separate the tumour from the adjacent adrenal but a pseudocapsule may be present, 
or the tumour may extend to the adrenal capsule. The border with the adjacent cortex may 
be irregular, with intermingling of tumour cells with cortical cells. 
The tumour cells vary considerably in size and shape and have a finely granular basophilic 
or amphophilic cytoplasm. The nuclei are usually round or oval with prominent nucleoli 
and may contain inclusion-like structure resulting from deep cytoplasmic invaginations. 
Cellular and nuclear pleomorphism is sometimes prominent (Fig. 2B) 17. Spindle cells are 
present in about 2% of cases, usually as a minor component. Haemorrhage and 
haemosiderin deposits are common. Mitotic figures are rare, with an average of one per 30 
high power fields reported in clinically benign lesions 18.  
 
 
    
A             B 
Fig. 2. Benign pheochromocytoma. A) Well-defined nest of cuboidal cells are separated by 
highly vascularized fibrous septa (“zellballen”). A granular, basophilic cytoplasm is usually 
identified surrounding slightly irregular nuclei; B) nuclear pleomorphisms are sometimes 
prominent. 
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2.3 Immunohistochemistry 
Specific diagnosis is usually based on morphology and confirmed by immunohisto-
chemistry. Pheochromocytomas are positive for chromogranin A. Other neural markers 
such as synaptophysin have been reported to be variably positive in cortical tumours. The 
absence of positivity for epithelial membrane antigen helps distinguish pheochromocytoma 
from renal cell carcinoma. Immunostaining for S100 protein will demonstrate sustentacular 
cells 19 which are usually arranged around the periphery of the cell nests where there is an 
alveolar arrangement (Fig. 3).  
 
 
   
A          B 
Fig. 3. Immunohistochemical staining. A) Positive cytoplasmic immunostain for 
chromogranin in the pheochromocytoma; B) Immunostain for S-100 protein shows intense 
dark staining of elongated nuclei of sustentacular cells. These are usually located near 
vascular channels. 
3. Familial pheochromocytoma 
Pheochromocytomas are considered to be unique neuroendocrine tumours since they can 
occur as part of several familial tumour syndromes. It is now recognized that the frequency 
of germline mutations in apparently sporadic presentations is as high as 15%–24% 11,20. 
However, the genetic basis of the majority of sporadic pheochromocytomas remains largely 
uncharacterized.  
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Familial pheochromocytomas are often multifocal or bilateral and generally present at an 
earlier age than sporadic pheochromocytoma. Germline mutations in six genes have been 
associated with familial pheochromocytoma, namely, the von Hippel-Lindau gene (VHL), 
which causes von Hippel-Lindau (VHL) syndrome, the RET gene, leading to multiple 
endocrine neoplasia type 2 (MEN 2), the neurofibromatosis type 1 gene (NF1), associated 
with neurofibromatosis type 1 (NF1) disease, and the genes encoding subunits B and D (and 
also rarely C) of mitochondrial succinate dehydrogenase (SDHB, SDHD, and SDHC), which 
are associated with familial paraganglioma/PPC. The recent description of mutations of the 
succinate dehydrogenase gene (SDH) has demonstrated a much stronger hereditary 
component than formerly thought. Currently, up to 24% of pheochromocytomas may have a 
genetic predisposition 11,20.  
The genetic susceptibility of malignant and benign pheochromocytomas is similar. However, 
advances in molecular genetics continue to underscore the importance of hereditary factors in 
the development of pheochromocytoma and propensity to malignancy. Malignant tumours 
have been reported in patients with germline mutations of RET, VHL, NF1 and the SDH genes 
21,22. On the other hand, malignant pheochromocytomas in the setting of MEN 2 occur less 
frequently than sporadic tumours 23,24,25,26. Which suggesting certain groups are 
predisposed to malignant disease. For example, patients with SDHB mutations are more likely 
to develop malignant disease and nondiploid tumours have also been found to be associated 
with malignancy. Gene expression and protein profiling are beginning to identify the genetic 
characteristics of malignant pheochromocytoma. However, the genetic changes that induce 
malignant disease remain unclear. 
4. Malignant disease 
Most pheochromocytomas are benign and curable by surgical resection, but some are 
clinically malignant 27. The pathologist cannot determine whether a tumour is benign or 
malignant based on histological features alone. Although extensive invasion of adjacent 
tissues can be considered an indicator of malignant potential, local invasiveness and 
malignant disease are not necessarily associated. Currently, there are no prognostic tests 
that can reliably predict which patients are at risk of developing metastatic disease. The 
World Health Organization tumour definition of a malignant pheochromocytoma is the 
presence of metastases, at site distant where chromaffin cells do not normally exist 28. 
Metastases occur most frequently to bone, liver, lungs and regional lymph nodes, and can 
appear as many as 20 years after initial presentation, which implies that life-long follow-up 
of patients (Fig. 4) 29.  
Some studies have suggested that the presence of necrosis, vascular invasion, extensive local 
invasion, and high rate of mitotic figures may indicate a malignant behavior in 
pheochromocytoma. Indeed, a recent study by Thompson used clinical features, histologic 
findings, and immunophenotypic studies to indentify parameters that may help distinguish 
benign from malignant pheochromocytoma of the Adrenal Gland Scaled Score (PASS) as a 
scoring system to differentiate benign from malignant pheochromocytomas. PASS is 
weighted for 12 specific histologic features that are more frequently identified in malignant 
pheochromocytomas. Factors such as tumour necrosis, high mitotic rate, tumour cell 
spindling, and vascular invasion are included in this scoring system (Fig. 5). Thompson 
found that tumours with ≥4 were biologically more aggressive than tumours with a PASS 
<4, which behaved in a benign fashion (Table 1) 30.  
www.intechopen.com
 Pheochromocytoma – A New View of the Old Problem 
 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Malignant pheochromocytoma. A and B) Multiple liver and lungs metastatic lesions 
were shown by computed tomography; C) Transition from the metastatic 
pheochromocytoma component (*) to the liver within the same section; D) By 
immunohistochemical was confirmed the presence of a metastatic pheochromocytoma with 
the characteristic chromogranin immunoreactivity in the pheochromocytos and the S-100 
protein immunoreactivity of the sustentacular cells which contrasted with negative liver 
tissue. 
A B
C D*
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C 
Fig. 5. Invasive malignant pheochromocytoma. A) A thick fibrous capsule is transgressed by 
the neoplastic cells with extension into surrounding addipose connective tissue in malignant 
pheochromocytoma; B) Extension into a vascular spaces is noted in a malignant 
pheochromocytoma. 
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Microscopic feature Score 
Extension into peri-adrenal adipose tissue 2 
Presence of large nests or diffuse growth 
(>10% of tumour volume)† 
2 
Central tumour necrosis (in the middle of large nests or confluent necrosis) 2 
High cellularity 2 
Tumour cell spindling even when focal  2 
Cellular monotony 2 
Mitotic figures >3/10 high-power field 2 
Atypical mitotic figures 2 
Vascular invasion* 1 
Capsular invasion 1 
Profound nuclear pleomorphism 1 
Nuclear hyperchromasia 1 
Total 20 
*Defined by direct extension into vessel lumen, intravascular attached tumour thrombi, and/ or tumour 
nests convered by endothelium identified in a capsular or extracapsular vessel. 
†Defined as 3-4 times the size of a zellballen or the normal size of the medullary paraganglia nest. 
Table 1. Pheochromocytoma of the Adrenal Gland Scoring Scale (PASS) 30. 
Additional markers that might be useful prognostic indicators in the pathological 
assessment of these tumours are sought. However, some studies with markers for important 
events in the cell cycle showed that less p21/WAF1 expression and aneuploidy correlated with 
malignant pheochromocytomas 31,32,33.  
4.1 Prognosis and predictive factors 
The rarity of this tumours and the resulting fragmented nature of studies, typically 
involving small numbers of patients, represent limiting factors to the development of 
effective treatments and diagnostic or prognostic markers for malignant disease.  The 
prognosis for patients with benign pheochromocytoma is primarily dependent upon a 
successful surgical resection and extend of preoperative complications related to 
hypertension. The usual prognosis of malignant pheochromocytoma is poor, with a 45-55% 
5-year survival 30,34,35,36,37,38. However, some patients may have indolent disease, with 
life expectancy of more than 20 years 39. Until further studies identify precise biological 
markers that can accurately predict the clinical behaviour of catecholamine-secreting 
tumours, it may be advisable for all pheochromocytoma patients to undergo lifelong 
hormonal monitoring and imaging studies to detect recurrence and metastases 40.  
5. Composite pheochromocytoma 
Ordinary pheochromocytoma is composed of polygonal to spindled cells arranged in an 
alveolar, trabecular, or solid pattern, often with a typical Zellballen appearance. Composite 
pheochromocytomas account for only 3% of both adrenal and extra-adrenal 
pheochromocytomas and can be associated with MEN 2A and phakomatoses 41,42. 
Composite pheochromocytoma is a rare tumour composed of typical pheochromocytoma 
and other components, most often neuroblastoma 43, ganglioneuroblastoma, or 
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ganglioneuroma in adult cases, and pediatric were very rare. Rare cases have displayed 
pheochromocytoma with other coexisting neural or neural crest–derived tumours such as 
malignant peripheral nerve sheath tumour. Little is known about the biologic potential, 
outcome, or molecular genetic profile.  
Because composite pheochromocytoma clinically resembles a typical pheochromocytoma, 
diagnosis is frequently made by the pathologist. The median age is 16 yr (9 to 24 yr) 43. 
The pathologic diagnosis of composite pheochromocytomas creates a clinical dilemma 
because it is not known whether the neuroblastic component results in therapeutic and 
prognostic implications different from those in ordinary pheochromocytoma. 
Neuroblastoma is the most immature of the neuroblastic tumours; the others are 
ganglioneuroblastoma and ganglioglioma (Table 2). These tumours are differentiated based 
on the amount of schwannian stroma and the presence or absence of ganglion cell 
differentiation. This dual phenotype is supported by light microscopy and corroborated by 
immunohistochemistry and ultrastructural findings. Prognosis of coexistence with 
pheochromocytoma and ganglioneuroblastoma or neuroblastoma is variable. 
 
Coexistence with No. of cases % 
Ganglioneuroma 41 70 
Ganglioneuroblastoma 7 11 
Neuroblastoma 4 9 
Schwannoma 4 7 
Neuroendocrine carcinoma 1 2 
Total 57 100 
Table 2. Cases of composite pheochromocytoma of adrenal gland 43. 
6. New insights on pheochromocytoma 
The molecular events involved in the malignant transformation of pheochromocytoma are 
poorly understood. There are also no reliable and uniformly accepted histopathologic 
criteria to distinguish benign from malignant pheochromocytoma. Unsupervised cluster 
analysis showed 3 main clusters of tumors that did not have complete concordance with the 
clinical and pathologic groupings of pheochromocytomas. Supervised cluster analysis 
showed almost completely separate clustering between benign and malignant tumours. The 
differentially expressed genes with known function belonged to 8 biologic process 
categories; signal transduction, transcription, protein transport, protein synthesis, smooth 
muscle contraction, ion transport, chemotaxis, and electron transport. Gene set enrichment 
analysis revealed significant correlation between the microarray profiles of malignant 
pheochromocytomas and several known molecular pathways associated with 
carcinogenesis and dedifferentiation. Ten differentially expressed genes had high diagnostic 
accuracy, and 5 of these genes (CFC1, FAM62B, HOMER1, LRRN3, TBX3, ADAMTS) in 
combination distinguishing benign versus malignant tumours. Differentially expressed 
genes between benign and malignant pheochromocytomas distinguish between these 
tumours with high diagnostic accuracy. These findings provide new insight into the genes 
and molecular pathways that may be involved in malignant pheochromocytomas 44. 
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7. Future directions 
Much attention has recently been devoted to pheochromocytoma as the understanding of 
this disease continues to improve. If it becomes widely available, it would greatly aid in the 
staging and management of malignant disease. Continually improving detection methods, 
especially screening of high-risk populations, will only contribute to the treatment and 
knowledge of these conditions in the future. It has become clear that many apparently 
sporadic pheochromocytomas have a genetic component. Not only has there been a great 
deal of attention directed toward the hereditary components, but better predictive molecular 
factors have been identified for malignant pheochromocytoma, which could lead to more 
effective genetic testing. In addition, microarray studies have identified a set of genes 
preferentially expressed in malignant pheochromocytoma. The combination of an 
identifiable hereditary component along with an understanding of the genetic and 
molecular defects in sporadic pheochromocytoma makes this a promising model and 
approach for insights into other cancers. The future is wide open for improvements in the 
understanding and treatment of this disease. 
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clinical diagnosis, laboratory and imaging, including differential diagnosis. Finally, the last section discusses the
treatment of pheochromocytoma showing clinical cases, a case about undiagnosed pheochromocytoma
complicated with multiple organ failure and other cases about catecholamine-secreting hereditary tumors.
Thus, this book shows the disease "pheochromocytoma" in a different perspective from the traditional
approach. Enjoy your reading.
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